Project description
Reinforcing immune cell therapy in the fight against cancer
The genetic engineering of immune cells to seek and destroy cancer cells has created a revolutionary treatment that has the potential to cure cancer. However, the introduction of this therapy into clinical practice is slowed by a lack of models to predict safety and efficacy as well as the absence of manufacturing standards and strategies for patient conditioning. The EU-funded T2EVOLVE project is bringing together scientists, medical professionals, policy-makers, industry and patient stakeholders to find a solution for existing problems. The project aims to deliver tools to promote education and the communication between healthcare providers and patients, laboratory models to determine the safety and effectiveness of new T cell therapies, and standardised methods of production and monitoring during treatment.
Objective
Immune cells that are empowered by gene-engineering to seek and destroy cancer cells (engineered T cell therapy) constitute a transformative novel treatment that has the potential to cure cancer. Multiple new versions of this therapy are being developed for distinct types of cancer but their introduction into clinical practice is hampered by a lack of standardized and validated models to predict safety and efficacy, customized manufacturing and monitoring to scale up production and clinical use to industry standard, and strategies for optimal patient conditioning. The T2EVOLVE consortium unites scientists and physicians, regulators and policy makers, SMEs, and patient stakeholders to tackle these challenges in an orchestrated multi-disciplinary multi-stakeholder approach. A core feature of this approach will be the embedding of patient stakeholders as contributing members of the team across all levels of the R&D process. The overall aim is the development of an innovation ecosystem that will accelerate the process of developing engineered T cell therapy in the EU. The project will deliver novel tools for education and for improving the communication between healthcare providers and patients, optimized laboratory models that can help determine how safe and effective new therapies with engineered T cells are, standardized methods in which these therapies are produced and monitored during treatment. The consortium members are innovators and pioneers in this field that are dedicated to bringing the EU to the forefront of the global engineered T cell therapy movement. This effort will ensure that EU citizens will continue to have access to the most innovative and best-available medical care, provide guidance on how to implement this novel treatment into the EU health care system in a sustainable way, and secure a leading role for Europe in this emerging field in medicine and science, the economy and society.
Fields of science
Keywords
Programme(s)
Funding Scheme
RIA - Research and Innovation actionCoordinator
97080 Wurzburg
Germany
See on map
Participants (29)
20132 Milano
See on map
WC1E 6BT London
See on map
1081 HV Amsterdam
See on map
92513 Boulogne Billancourt
See on map
75654 Paris
See on map
63225 Langen
See on map
00165 Roma
See on map
1090 Wien
See on map
08036 Barcelona
See on map
Legal entity other than a subcontractor which is affiliated or legally linked to a participant. The entity carries out work under the conditions laid down in the Grant Agreement, supplies goods or provides services for the action, but did not sign the Grant Agreement. A third party abides by the rules applicable to its related participant under the Grant Agreement with regard to eligibility of costs and control of expenditure.
08036 Barcelona
See on map
80686 Munchen
See on map
80333 Muenchen
See on map
97076 Wurzburg
See on map
The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.
Participation ended
1210 Bruxelles / Brussel
See on map
3631 Maasmechelen
See on map
The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.
31080 Pamplona
See on map
3062 PA Rotterdam
See on map
51429 Bergisch Gladbach
See on map
08041 Barcelona
See on map
4354 ESCH SUR ALZETTE
See on map
The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.
51373 Leverkusen
See on map
2340 Beerse
See on map
92284 Courbevoie
See on map
8152 Glattpark
See on map
2514 AA Den Haag
See on map
The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.
2333 BE Leiden
See on map
2017 Boudry
See on map
85521 Riemerling
See on map
The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.
2333 AA Leiden
See on map